Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06283589 · ClinicalTrials.gov registry record · Phase 1
The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis
A Phase 1 study, sponsored by Inozyme Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT06283589 is a Phase 1 study that has completed, run by Inozyme Pharma. The registered enrollment target is 11 participants.
The verdict
NCT06283589, a Phase 1 study, has completed, sponsored by Inozyme Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if multiple doses of INZ-701, given once per week over 4 weeks are safe and increase pyrophosphate (PPi) levels in hemodialysis-dependent (HD) end stage kidney disease (ESKD) study participants who have low PPi levels. In addition, the effect of hemodialysis on the pharmacokinetics of INZ-701 and PPi levels will be evaluated.
Interventions
- DRUG INZ-701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-02-12 |
| Est. Completion | 2024-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06283589
The ClinicalTrials.gov registry entry for NCT06283589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inozyme Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INZ-701 is the first listed.
NCT06283589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06283589 about?
NCT06283589 is a clinical study titled "The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis". The purpose of this study is to determine if multiple doses of INZ-701, given once per week over 4 weeks are safe and increase pyrophosphate (PPi) levels in hemodialysis-dependent (HD) end stage kidney disease (ESKD) study participants who have low PPi levels. In addition, the effect of hemodialysis...
What is the current status of trial NCT06283589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2024-02-12. Estimated completion is 2024-12-13.
What interventions are being tested in trial NCT06283589?
The interventions under investigation include: INZ-701 (DRUG).
Who is sponsoring clinical trial NCT06283589?
This trial is sponsored by Inozyme Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.